CMS Administrator Tavenner provides public assurances that the agency will not reintroduce a proposal to remove antidepressants, antipsychotics and immunosuppressants from protected status in the Medicare Part D program.
CMS Administrator Marilyn Tavenner pledged at a recent congressional hearing that the agency’s controversial proposal to eliminate some of the Medicare Part D protected classes will not be reintroduced on her watch.
“I’m not interested in bringing back the [Part D proposal regarding] drug categories,” Tavenner told the House Oversight and Government...
Create an account to read this article
Already a subscriber?
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
Six deaths early in treatment inspired a new safety requirement for Biogen/Eisai’s Leqembi to promote early identification of patients affected by the well-known risk of amyloid-related imaging abnormalities with edema (ARIA-E).
The CBER director rejected Pfizer’s assertions that pediatric dosing gaps, supply constraints and comparative mRNA content justify keeping the vaccine under emergency use authorization for younger children.
The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.
The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.
All COVID-19 vaccines are labeled for individuals 65 years and older or those with risk factors, and Moderna’s Spikevax is the only vaccine indicated for children as young as six months now that Pfizer’s emergency use authorization has been rescinded.
The state’s prescription drug affordability board could be the first to recommend an upper payment limit for a prescription drug.
